Comparison · NCT01885182-sae
Oxycodone/Naloxone vs Oxycodone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oxycodone/Naloxone vs Oxycodone: serious adverse events. Trial comparisons, record NCT01885182-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01885182-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.123 | 0.0746 | 0.196 | wilson | |
| Risk in group 2 | 0.108 | 0.0629 | 0.18 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0147 | -0.0715 | 0.1 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.55 | 2.35 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 0.509 | 2.62 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Oxycodone/Naloxone than on Oxycodone | 68 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oxycodone/Naloxone | 5/2.5mg, 10/5mg, 20/10mg or 40/20mg~Oxycodone/Naloxone | 14 | 114 | EG000 |
| Group 2 | Oxycodone | 5mg, 10mg, 20mg or 40mg~Oxycodone | 12 | 111 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The adverse event data were collected from 2013 Jun to 2014 Aug, which is about 14 months. The time frame of AE collection for each subject is about 6 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
- NCT number
- NCT01885182
- Phases
- PHASE3
- Conditions
- Cancer, Pain
- Interventions
- Oxycodone/Naloxone, Oxycodone
- Lead sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
- Results first posted
- 2019-09-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01885182?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01885182-sae